Aveo Capital Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
Sell
-23,246
Closed -$2.21M 159
2018
Q2
$2.21M Buy
+23,246
New +$2.14M 0.98% 20
2017
Q4
Sell
-22,088
Closed -$1.91M 155
2017
Q3
$1.91M Buy
+22,088
New +$1.77M 0.66% 20
2017
Q2
Sell
-24,062
Closed -$1.67M 145
2017
Q1
$1.67M Buy
+24,062
New +$1.62M 0.61% 22

Other funds holding XBI

Aveo Capital Partners's XBI Position: Q3 2018 in Review

Aveo Capital Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2018, closing a stake of 23,246 shares — an estimated $2.21M sold.

Aveo Capital Partners first reported a position in XBI in Q1 2017 and held it in 3 quarters. The position peaked at $2.21M in Q2 2018. 432 funds tracked by Wall St. Rank hold XBI as of Q3 2018.

  • Aveo Capital Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2018 after selling out during the quarter.
  • Aveo Capital Partners sold 23,246 State Street SPDR S&P Biotech ETF shares in Q3 2018, an estimated $2.21M.
  • Aveo Capital Partners first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and held it in 3 quarters.
  • Aveo Capital Partners's State Street SPDR S&P Biotech ETF position peaked at $2.21M in Q2 2018.
  • 432 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2018.

Based on Aveo Capital Partners's 13F filing for Q3 2018, filed 9 Nov 2018.